Pilot Efficacy Study of PI-88 With Docetaxel to Treat Prostate Cancer
Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
Docetaxel (Taxotere) is an approved chemotherapeutic drug for the treatment of
androgen-independent prostate cancer. The aim of the study is to investigate whether addition
of the investigational drug PI-88 will increase the efficacy of docetaxel in this disease.
PI-88 inhibits cancer growth by inhibiting the development of new blood vessels and starving
the tumour of oxygen and nutrients (anti-angiogenic). Because PI-88 and docetaxel have
different mechanisms of action, they are expected to have increased (synergistic) activity
when combined.
Phase:
Phase 2
Details
Lead Sponsor:
Progen Pharmaceuticals
Collaborators:
Aventis Pharmaceuticals Northern Sydney and Central Coast Area Health Service